Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases.Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.
Market Analysis and Insights: Global Primary Sclerosing Cholangitis Treatment Market
The global Primary Sclerosing Cholangitis Treatment market size is projected to reach US$ million by 2026, from US$ million in 2020, at a CAGR of % during 2021-2026.
Global Primary Sclerosing Cholangitis Treatment Scope and Segment
The global Primary Sclerosing Cholangitis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Sclerosing Cholangitis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
By the type, the market is primarily split into
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
By the application, this report covers the following segments
Hospital
Clinics
Other
Competitive Landscape:
The Primary Sclerosing Cholangitis Treatment key manufacturers in this market include:
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals
Market Analysis and Insights: Global Primary Sclerosing Cholangitis Treatment Market
The global Primary Sclerosing Cholangitis Treatment market size is projected to reach US$ million by 2026, from US$ million in 2020, at a CAGR of % during 2021-2026.
Global Primary Sclerosing Cholangitis Treatment Scope and Segment
The global Primary Sclerosing Cholangitis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Sclerosing Cholangitis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
By the type, the market is primarily split into
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
By the application, this report covers the following segments
Hospital
Clinics
Other
Competitive Landscape:
The Primary Sclerosing Cholangitis Treatment key manufacturers in this market include:
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals
1 Market Overview of Primary Sclerosing Cholangitis Treatment
1.1 Primary Sclerosing Cholangitis Treatment Market Overview
1.1.1 Primary Sclerosing Cholangitis Treatment Product Scope
1.1.2 Market Status and Outlook
1.2 Global Primary Sclerosing Cholangitis Treatment Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2015-2026)
1.4 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2015-2020)
1.5 Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.1 North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.2 Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.3 China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.5 Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
2 Primary Sclerosing Cholangitis Treatment Market Overview by Type
2.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2015-2020)
2.3 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2021-2026)
2.4 Liver Transplantation Operation
2.5 UDCA Drugs
2.6 PSC Drugs
3 Primary Sclerosing Cholangitis Treatment Market Overview by Application
3.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2015-2020)
3.3 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinics
3.6 Other
4 Global Primary Sclerosing Cholangitis Treatment Competition Analysis by Players
4.1 Global Primary Sclerosing Cholangitis Treatment Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2019)
4.3 Date of Key Manufacturers Enter into Primary Sclerosing Cholangitis Treatment Market
4.4 Global Top Players Primary Sclerosing Cholangitis Treatment Headquarters and Area Served
4.5 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Primary Sclerosing Cholangitis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Allergan
5.1.1 Allergan Profile
5.1.2 Allergan Main Business and Company’s Total Revenue
5.1.3 Allergan Products, Services and Solutions
5.1.4 Allergan Revenue (US$ Million) (2015-2020)
5.1.5 Allergan Recent Development and Reaction to Covid-19
5.2 Glenmark
5.2.1 Glenmark Profile
5.2.2 Glenmark Main Business and Company’s Total Revenue
5.2.3 Glenmark Products, Services and Solutions
5.2.4 Glenmark Revenue (US$ Million) (2015-2020)
5.2.5 Glenmark Recent Development and Reaction to Covid-19
5.3 Impax Laboratories
5.5.1 Impax Laboratories Profile
5.3.2 Impax Laboratories Main Business and Company’s Total Revenue
5.3.3 Impax Laboratories Products, Services and Solutions
5.3.4 Impax Laboratories Revenue (US$ Million) (2015-2020)
5.3.5 Mylan Recent Development and Reaction to Covid-19
5.4 Mylan
5.4.1 Mylan Profile
5.4.2 Mylan Main Business and Company’s Total Revenue
5.4.3 Mylan Products, Services and Solutions
5.4.4 Mylan Revenue (US$ Million) (2015-2020)
5.4.5 Mylan Recent Development and Reaction to Covid-19
5.5 Teva Pharmaceuticals
5.5.1 Teva Pharmaceuticals Profile
5.5.2 Teva Pharmaceuticals Main Business and Company’s Total Revenue
5.5.3 Teva Pharmaceuticals Products, Services and Solutions
5.5.4 Teva Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.5.5 Teva Pharmaceuticals Recent Development and Reaction to Covid-19
5.6 Dr. Falk Pharma
5.6.1 Dr. Falk Pharma Profile
5.6.2 Dr. Falk Pharma Main Business and Company’s Total Revenue
5.6.3 Dr. Falk Pharma Products, Services and Solutions
5.6.4 Dr. Falk Pharma Revenue (US$ Million) (2015-2020)
5.6.5 Dr. Falk Pharma Recent Development and Reaction to Covid-19
5.7 Daewoong Pharmaceutical
5.7.1 Daewoong Pharmaceutical Profile
5.7.2 Daewoong Pharmaceutical Main Business and Company’s Total Revenue
5.7.3 Daewoong Pharmaceutical Products, Services and Solutions
5.7.4 Daewoong Pharmaceutical Revenue (US$ Million) (2015-2020)
5.7.5 Daewoong Pharmaceutical Recent Development and Reaction to Covid-19
5.8 Epic Pharma
5.8.1 Epic Pharma Profile
5.8.2 Epic Pharma Main Business and Company’s Total Revenue
5.8.3 Epic Pharma Products, Services and Solutions
5.8.4 Epic Pharma Revenue (US$ Million) (2015-2020)
5.8.5 Epic Pharma Recent Development and Reaction to Covid-19
5.9 Mitsubishi Tanabe Pharma
5.9.1 Mitsubishi Tanabe Pharma Profile
5.9.2 Mitsubishi Tanabe Pharma Main Business and Company’s Total Revenue
5.9.3 Mitsubishi Tanabe Pharma Products, Services and Solutions
5.9.4 Mitsubishi Tanabe Pharma Revenue (US$ Million) (2015-2020)
5.9.5 Mitsubishi Tanabe Pharma Recent Development and Reaction to Covid-19
5.10 Lannett
5.10.1 Lannett Profile
5.10.2 Lannett Main Business and Company’s Total Revenue
5.10.3 Lannett Products, Services and Solutions
5.10.4 Lannett Revenue (US$ Million) (2015-2020)
5.10.5 Lannett Recent Development and Reaction to Covid-19
5.11 Bruschettini
5.11.1 Bruschettini Profile
5.11.2 Bruschettini Main Business and Company’s Total Revenue
5.11.3 Bruschettini Products, Services and Solutions
5.11.4 Bruschettini Revenue (US$ Million) (2015-2020)
5.11.5 Bruschettini Recent Development and Reaction to Covid-19
5.12 Shanghai Pharma
5.12.1 Shanghai Pharma Profile
5.12.2 Shanghai Pharma Main Business and Company’s Total Revenue
5.12.3 Shanghai Pharma Products, Services and Solutions
5.12.4 Shanghai Pharma Revenue (US$ Million) (2015-2020)
5.12.5 Shanghai Pharma Recent Development and Reaction to Covid-19
5.13 Grindeks
5.13.1 Grindeks Profile
5.13.2 Grindeks Main Business and Company’s Total Revenue
5.13.3 Grindeks Products, Services and Solutions
5.13.4 Grindeks Revenue (US$ Million) (2015-2020)
5.13.5 Grindeks Recent Development and Reaction to Covid-19
5.14 Acorda Therapeutics
5.14.1 Acorda Therapeutics Profile
5.14.2 Acorda Therapeutics Main Business and Company’s Total Revenue
5.14.3 Acorda Therapeutics Products, Services and Solutions
5.14.4 Acorda Therapeutics Revenue (US$ Million) (2015-2020)
5.14.5 Acorda Therapeutics Recent Development and Reaction to Covid-19
5.15 Gilead Sciences
5.15.1 Gilead Sciences Profile
5.15.2 Gilead Sciences Main Business and Company’s Total Revenue
5.15.3 Gilead Sciences Products, Services and Solutions
5.15.4 Gilead Sciences Revenue (US$ Million) (2015-2020)
5.15.5 Gilead Sciences Recent Development and Reaction to Covid-19
5.16 Intercept Pharmaceuticals
5.16.1 Intercept Pharmaceuticals Profile
5.16.2 Intercept Pharmaceuticals Main Business and Company’s Total Revenue
5.16.3 Intercept Pharmaceuticals Products, Services and Solutions
5.16.4 Intercept Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.16.5 Intercept Pharmaceuticals Recent Development and Reaction to Covid-19
5.17 Shire Plc
5.17.1 Shire Plc Profile
5.17.2 Shire Plc Main Business and Company’s Total Revenue
5.17.3 Shire Plc Products, Services and Solutions
5.17.4 Shire Plc Revenue (US$ Million) (2015-2020)
5.17.5 Shire Plc Recent Development and Reaction to Covid-19
5.18 NGM Biopharmaceuticals
5.18.1 NGM Biopharmaceuticals Profile
5.18.2 NGM Biopharmaceuticals Main Business and Company’s Total Revenue
5.18.3 NGM Biopharmaceuticals Products, Services and Solutions
5.18.4 NGM Biopharmaceuticals Revenue (US$ Million) (2015-2020)
5.18.5 NGM Biopharmaceuticals Recent Development and Reaction to Covid-19
5.19 Conatus Pharmaceuticals
5.19.1 Conatus Pharmaceuticals Profile
5.19.2 Conatus Pharmaceuticals Main Business and Company’s Total Revenue
5.19.3 Conatus Pharmaceuticals Products, Services and Solutions
5.19.4 Conatus Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.19.5 Conatus Pharmaceuticals Recent Development and Reaction to Covid-19
5.20 Durect Corporation
5.20.1 Durect Corporation Profile
5.20.2 Durect Corporation Main Business and Company’s Total Revenue
5.20.3 Durect Corporation Products, Services and Solutions
5.20.4 Durect Corporation Revenue (US$ Million) (2015-2020)
5.20.5 Durect Corporation Recent Development and Reaction to Covid-19
5.21 Sirnaomics
5.21.1 Sirnaomics Profile
5.21.2 Sirnaomics Main Business and Company’s Total Revenue
5.21.3 Sirnaomics Products, Services and Solutions
5.21.4 Sirnaomics Revenue (US$ Million) (2015-2020)
5.21.5 Sirnaomics Recent Development and Reaction to Covid-19
5.22 Shenzhen HighTide Biopharmaceuticals
5.22.1 Shenzhen HighTide Biopharmaceuticals Profile
5.22.2 Shenzhen HighTide Biopharmaceuticals Main Business and Company’s Total Revenue
5.22.3 Shenzhen HighTide Biopharmaceuticals Products, Services and Solutions
5.22.4 Shenzhen HighTide Biopharmaceuticals Revenue (US$ Million) (2015-2020)
5.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development and Reaction to Covid-19
6 North America Primary Sclerosing Cholangitis Treatment by Players and by Application
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
7 Europe Primary Sclerosing Cholangitis Treatment by Players and by Application
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
8 China Primary Sclerosing Cholangitis Treatment by Players and by Application
8.1 China Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
8.2 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
9 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment by Players and by Application
9.1 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
10 Latin America Primary Sclerosing Cholangitis Treatment by Players and by Application
10.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
10.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
11 Middle East & Africa Primary Sclerosing Cholangitis Treatment by Players and by Application
11.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
12 Primary Sclerosing Cholangitis Treatment Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
1.1 Primary Sclerosing Cholangitis Treatment Market Overview
1.1.1 Primary Sclerosing Cholangitis Treatment Product Scope
1.1.2 Market Status and Outlook
1.2 Global Primary Sclerosing Cholangitis Treatment Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2015-2026)
1.4 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2015-2020)
1.5 Global Primary Sclerosing Cholangitis Treatment Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.1 North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.2 Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.3 China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.5 Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2015-2026)
2 Primary Sclerosing Cholangitis Treatment Market Overview by Type
2.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2015-2020)
2.3 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2021-2026)
2.4 Liver Transplantation Operation
2.5 UDCA Drugs
2.6 PSC Drugs
3 Primary Sclerosing Cholangitis Treatment Market Overview by Application
3.1 Global Primary Sclerosing Cholangitis Treatment Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2015-2020)
3.3 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinics
3.6 Other
4 Global Primary Sclerosing Cholangitis Treatment Competition Analysis by Players
4.1 Global Primary Sclerosing Cholangitis Treatment Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2019)
4.3 Date of Key Manufacturers Enter into Primary Sclerosing Cholangitis Treatment Market
4.4 Global Top Players Primary Sclerosing Cholangitis Treatment Headquarters and Area Served
4.5 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Primary Sclerosing Cholangitis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Allergan
5.1.1 Allergan Profile
5.1.2 Allergan Main Business and Company’s Total Revenue
5.1.3 Allergan Products, Services and Solutions
5.1.4 Allergan Revenue (US$ Million) (2015-2020)
5.1.5 Allergan Recent Development and Reaction to Covid-19
5.2 Glenmark
5.2.1 Glenmark Profile
5.2.2 Glenmark Main Business and Company’s Total Revenue
5.2.3 Glenmark Products, Services and Solutions
5.2.4 Glenmark Revenue (US$ Million) (2015-2020)
5.2.5 Glenmark Recent Development and Reaction to Covid-19
5.3 Impax Laboratories
5.5.1 Impax Laboratories Profile
5.3.2 Impax Laboratories Main Business and Company’s Total Revenue
5.3.3 Impax Laboratories Products, Services and Solutions
5.3.4 Impax Laboratories Revenue (US$ Million) (2015-2020)
5.3.5 Mylan Recent Development and Reaction to Covid-19
5.4 Mylan
5.4.1 Mylan Profile
5.4.2 Mylan Main Business and Company’s Total Revenue
5.4.3 Mylan Products, Services and Solutions
5.4.4 Mylan Revenue (US$ Million) (2015-2020)
5.4.5 Mylan Recent Development and Reaction to Covid-19
5.5 Teva Pharmaceuticals
5.5.1 Teva Pharmaceuticals Profile
5.5.2 Teva Pharmaceuticals Main Business and Company’s Total Revenue
5.5.3 Teva Pharmaceuticals Products, Services and Solutions
5.5.4 Teva Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.5.5 Teva Pharmaceuticals Recent Development and Reaction to Covid-19
5.6 Dr. Falk Pharma
5.6.1 Dr. Falk Pharma Profile
5.6.2 Dr. Falk Pharma Main Business and Company’s Total Revenue
5.6.3 Dr. Falk Pharma Products, Services and Solutions
5.6.4 Dr. Falk Pharma Revenue (US$ Million) (2015-2020)
5.6.5 Dr. Falk Pharma Recent Development and Reaction to Covid-19
5.7 Daewoong Pharmaceutical
5.7.1 Daewoong Pharmaceutical Profile
5.7.2 Daewoong Pharmaceutical Main Business and Company’s Total Revenue
5.7.3 Daewoong Pharmaceutical Products, Services and Solutions
5.7.4 Daewoong Pharmaceutical Revenue (US$ Million) (2015-2020)
5.7.5 Daewoong Pharmaceutical Recent Development and Reaction to Covid-19
5.8 Epic Pharma
5.8.1 Epic Pharma Profile
5.8.2 Epic Pharma Main Business and Company’s Total Revenue
5.8.3 Epic Pharma Products, Services and Solutions
5.8.4 Epic Pharma Revenue (US$ Million) (2015-2020)
5.8.5 Epic Pharma Recent Development and Reaction to Covid-19
5.9 Mitsubishi Tanabe Pharma
5.9.1 Mitsubishi Tanabe Pharma Profile
5.9.2 Mitsubishi Tanabe Pharma Main Business and Company’s Total Revenue
5.9.3 Mitsubishi Tanabe Pharma Products, Services and Solutions
5.9.4 Mitsubishi Tanabe Pharma Revenue (US$ Million) (2015-2020)
5.9.5 Mitsubishi Tanabe Pharma Recent Development and Reaction to Covid-19
5.10 Lannett
5.10.1 Lannett Profile
5.10.2 Lannett Main Business and Company’s Total Revenue
5.10.3 Lannett Products, Services and Solutions
5.10.4 Lannett Revenue (US$ Million) (2015-2020)
5.10.5 Lannett Recent Development and Reaction to Covid-19
5.11 Bruschettini
5.11.1 Bruschettini Profile
5.11.2 Bruschettini Main Business and Company’s Total Revenue
5.11.3 Bruschettini Products, Services and Solutions
5.11.4 Bruschettini Revenue (US$ Million) (2015-2020)
5.11.5 Bruschettini Recent Development and Reaction to Covid-19
5.12 Shanghai Pharma
5.12.1 Shanghai Pharma Profile
5.12.2 Shanghai Pharma Main Business and Company’s Total Revenue
5.12.3 Shanghai Pharma Products, Services and Solutions
5.12.4 Shanghai Pharma Revenue (US$ Million) (2015-2020)
5.12.5 Shanghai Pharma Recent Development and Reaction to Covid-19
5.13 Grindeks
5.13.1 Grindeks Profile
5.13.2 Grindeks Main Business and Company’s Total Revenue
5.13.3 Grindeks Products, Services and Solutions
5.13.4 Grindeks Revenue (US$ Million) (2015-2020)
5.13.5 Grindeks Recent Development and Reaction to Covid-19
5.14 Acorda Therapeutics
5.14.1 Acorda Therapeutics Profile
5.14.2 Acorda Therapeutics Main Business and Company’s Total Revenue
5.14.3 Acorda Therapeutics Products, Services and Solutions
5.14.4 Acorda Therapeutics Revenue (US$ Million) (2015-2020)
5.14.5 Acorda Therapeutics Recent Development and Reaction to Covid-19
5.15 Gilead Sciences
5.15.1 Gilead Sciences Profile
5.15.2 Gilead Sciences Main Business and Company’s Total Revenue
5.15.3 Gilead Sciences Products, Services and Solutions
5.15.4 Gilead Sciences Revenue (US$ Million) (2015-2020)
5.15.5 Gilead Sciences Recent Development and Reaction to Covid-19
5.16 Intercept Pharmaceuticals
5.16.1 Intercept Pharmaceuticals Profile
5.16.2 Intercept Pharmaceuticals Main Business and Company’s Total Revenue
5.16.3 Intercept Pharmaceuticals Products, Services and Solutions
5.16.4 Intercept Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.16.5 Intercept Pharmaceuticals Recent Development and Reaction to Covid-19
5.17 Shire Plc
5.17.1 Shire Plc Profile
5.17.2 Shire Plc Main Business and Company’s Total Revenue
5.17.3 Shire Plc Products, Services and Solutions
5.17.4 Shire Plc Revenue (US$ Million) (2015-2020)
5.17.5 Shire Plc Recent Development and Reaction to Covid-19
5.18 NGM Biopharmaceuticals
5.18.1 NGM Biopharmaceuticals Profile
5.18.2 NGM Biopharmaceuticals Main Business and Company’s Total Revenue
5.18.3 NGM Biopharmaceuticals Products, Services and Solutions
5.18.4 NGM Biopharmaceuticals Revenue (US$ Million) (2015-2020)
5.18.5 NGM Biopharmaceuticals Recent Development and Reaction to Covid-19
5.19 Conatus Pharmaceuticals
5.19.1 Conatus Pharmaceuticals Profile
5.19.2 Conatus Pharmaceuticals Main Business and Company’s Total Revenue
5.19.3 Conatus Pharmaceuticals Products, Services and Solutions
5.19.4 Conatus Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.19.5 Conatus Pharmaceuticals Recent Development and Reaction to Covid-19
5.20 Durect Corporation
5.20.1 Durect Corporation Profile
5.20.2 Durect Corporation Main Business and Company’s Total Revenue
5.20.3 Durect Corporation Products, Services and Solutions
5.20.4 Durect Corporation Revenue (US$ Million) (2015-2020)
5.20.5 Durect Corporation Recent Development and Reaction to Covid-19
5.21 Sirnaomics
5.21.1 Sirnaomics Profile
5.21.2 Sirnaomics Main Business and Company’s Total Revenue
5.21.3 Sirnaomics Products, Services and Solutions
5.21.4 Sirnaomics Revenue (US$ Million) (2015-2020)
5.21.5 Sirnaomics Recent Development and Reaction to Covid-19
5.22 Shenzhen HighTide Biopharmaceuticals
5.22.1 Shenzhen HighTide Biopharmaceuticals Profile
5.22.2 Shenzhen HighTide Biopharmaceuticals Main Business and Company’s Total Revenue
5.22.3 Shenzhen HighTide Biopharmaceuticals Products, Services and Solutions
5.22.4 Shenzhen HighTide Biopharmaceuticals Revenue (US$ Million) (2015-2020)
5.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development and Reaction to Covid-19
6 North America Primary Sclerosing Cholangitis Treatment by Players and by Application
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
7 Europe Primary Sclerosing Cholangitis Treatment by Players and by Application
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
8 China Primary Sclerosing Cholangitis Treatment by Players and by Application
8.1 China Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
8.2 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
9 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment by Players and by Application
9.1 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
10 Latin America Primary Sclerosing Cholangitis Treatment by Players and by Application
10.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
10.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
11 Middle East & Africa Primary Sclerosing Cholangitis Treatment by Players and by Application
11.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Application (2015-2020)
12 Primary Sclerosing Cholangitis Treatment Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
